Market Closed -
Nasdaq
04:00:00 2024-05-02 pm EDT
|
5-day change
|
1st Jan Change
|
4.07
USD
|
+4.09%
|
|
+27.59%
|
-18.76%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
273.2
|
154.7
|
49.41
|
52.9
|
124.1
|
111.3
|
-
|
-
|
Enterprise Value (EV)
1 |
273.2
|
154.7
|
49.41
|
52.9
|
124.1
|
111.3
|
111.3
|
111.3
|
P/E ratio
|
-2.17
x
|
-1.73
x
|
-0.39
x
|
-0.56
x
|
-1.98
x
|
-1.9
x
|
-2.15
x
|
-7.02
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
15.5
x
|
16.5
x
|
37.4
x
|
35.5
x
|
223
x
|
4.88
x
|
1.25
x
|
EV / Revenue
|
-
|
15.5
x
|
16.5
x
|
37.4
x
|
35.5
x
|
223
x
|
4.88
x
|
1.25
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-3,951,554
x
|
-4,254,944
x
|
-
|
-
|
-
|
-
|
-2,420,326
x
|
8,564,231
x
|
FCF Yield
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
-0%
|
0%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,341
|
3,941
|
5,865
|
17,176
|
24,773
|
27,355
|
-
|
-
|
Reference price
2 |
81.75
|
39.25
|
8.425
|
3.080
|
5.010
|
4.070
|
4.070
|
4.070
|
Announcement Date
|
3/16/20
|
3/24/21
|
3/31/22
|
3/29/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10
|
3
|
1.414
|
3.5
|
0.5
|
22.83
|
88.88
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-77.09
|
-81.42
|
-89.84
|
-50.92
|
-47.14
|
-56.48
|
-48.37
|
4.712
|
Operating Margin
|
-
|
-814.2%
|
-2,994.53%
|
-3,600.78%
|
-1,346.71%
|
-11,296.25%
|
-211.92%
|
5.3%
|
Earnings before Tax (EBT)
1 |
-76.28
|
-84.23
|
-84.94
|
-39.7
|
-54.19
|
-60.27
|
-63.67
|
-26.8
|
Net income
1 |
-76.28
|
-84.23
|
-84.94
|
-43.48
|
-54.19
|
-60.27
|
-63.67
|
-26.07
|
Net margin
|
-
|
-842.34%
|
-2,831.2%
|
-3,074.82%
|
-1,548.23%
|
-12,053.33%
|
-278.92%
|
-29.33%
|
EPS
2 |
-37.75
|
-22.75
|
-21.50
|
-5.530
|
-2.530
|
-2.137
|
-1.897
|
-0.5800
|
Free Cash Flow
|
-69.13
|
-36.36
|
-
|
-
|
-
|
-
|
-46
|
13
|
FCF margin
|
-
|
-363.55%
|
-
|
-
|
-
|
-
|
-201.53%
|
14.63%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/24/21
|
3/31/22
|
3/29/23
|
3/18/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
3
|
0.346
|
1
|
-
|
0.068
|
-
|
3.5
|
-
|
-
|
0.125
|
0.125
|
0.125
|
0.125
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-14.87
|
-46.65
|
-20.59
|
-8.008
|
-9.38
|
-12.94
|
-12.04
|
-11.62
|
-11.33
|
-13.21
|
-13.8
|
-14.1
|
-15.03
|
-15.83
|
Operating Margin
|
-
|
-1,555.07%
|
-5,951.16%
|
-800.8%
|
-
|
-19,023.53%
|
-
|
-331.97%
|
-
|
-
|
-11,040%
|
-11,280%
|
-12,026.66%
|
-12,666.66%
|
Earnings before Tax (EBT)
1 |
-7.044
|
-46.68
|
-20.79
|
-8.295
|
-9.484
|
-1.126
|
-9.107
|
-16.65
|
-11.84
|
-16.59
|
-14
|
-14.5
|
-15.43
|
-16.47
|
Net income
1 |
-7.044
|
-46.68
|
-20.79
|
-12.08
|
-9.484
|
-1.126
|
-9.107
|
-16.65
|
-11.84
|
-16.59
|
-14
|
-14.5
|
-15.43
|
-16.47
|
Net margin
|
-
|
-1,556.1%
|
-6,008.96%
|
-1,207.7%
|
-
|
-1,655.88%
|
-
|
-475.83%
|
-
|
-
|
-11,200%
|
-11,600%
|
-12,346.66%
|
-13,173.34%
|
EPS
2 |
-1.750
|
-11.25
|
-3.500
|
-2.080
|
-1.480
|
-
|
-0.5400
|
-0.9200
|
-0.4800
|
-0.6400
|
-0.5133
|
-0.5300
|
-0.5567
|
-0.5400
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/15/21
|
3/31/22
|
5/13/22
|
8/11/22
|
11/14/22
|
3/29/23
|
5/11/23
|
8/8/23
|
11/13/23
|
3/18/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-69.1
|
-36.4
|
-
|
-
|
-
|
-
|
-46
|
13
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
6.31
|
1.34
|
-
|
-
|
-
|
-
|
5
|
6
|
Capex / Sales
|
-
|
13.36%
|
-
|
-
|
-
|
-
|
21.91%
|
6.75%
|
Announcement Date
|
3/16/20
|
3/24/21
|
3/31/22
|
3/29/23
|
3/18/24
|
-
|
-
|
-
|
Last Close Price
4.07
USD Average target price
19.5
USD Spread / Average Target +379.12% Consensus |
1st Jan change
|
Capi.
|
---|
| -18.76% | 107M | | +26.28% | 42.68B | | -3.99% | 42.4B | | +45.32% | 40.04B | | -6.20% | 28.31B | | +6.36% | 24.94B | | -21.47% | 18.96B | | +27.58% | 12.3B | | -2.75% | 11.95B | | -2.02% | 11.55B |
Other Biotechnology & Medical Research
|